Follicular Lymphoma Clinical Trials

Follicular Lymphoma Clinical Trials

Follicular Lymphoma Clinical Trials are a good option for patients who may not have found success with standard treatment or those who are looking for new and alternative treatment options from medical professionals that aren’t available in standard care. Follicular Lymphoma is a subtype that makes up 20-30% of all non-Hodgkin Lymphoma (NHL) cases.

What are Follicular Lymphoma Clinical Trials?

Follicular lymphoma clinical trials are designed for researchers to learn whether new treatments and procedures are efficient, beneficial and/or safe. The clinical trials may involve new drugs, new combinations of drugs, new surgical procedures or devices, or new procedures using existing treatments. It is different from standard medical care in that doctors diagnose and treat illnesses, whereas in clinical trials, researchers attempt to get new knowledge and information that has the potential of improving treatment for participants and future follicular lymphoma patients. By joining a follicular lymphoma clinical trial, you are also helping others who will be treated for follicular lymphoma.

What are the Benefits of Joining a Follicular Lymphoma Clinical Trial?

The benefits of joining a Follicular Lymphoma trial are that you have more options available for treatment that may be more effective for your specific case, you are more closely observed and monitored by medical professionals, treatments are more personalized than the standard of care, and you are also helping others with similar conditions.

What are Some Current Follicular Lymphoma Clinical Trial Treatments?

Some treatments that are being studied in NHL clinical trials include the immunotherapy drugs:

  • Ofatumumab (Arzerra®) is being evaluated and combined with other medications for diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and follicular lymphoma.
  • Obinutuzumab (Gazyva®), is an anti-CD20 antibody and is being researched for the treatment of refractory Follicular Lymphoma.
  • Nivolumab (Opdivo®), is an anti-programmed death-1 (anti-PD1) antibody that is being evaluated for the treatment of relapsed or refractory Follicular Lymphoma.
  • Pembrolizumab (Keytruda®), is being evaluated for the treatment of Follicular Lymphoma among other lymphoma types.

If you are considering joining a Follicular Lymphoma clinical trial, consult with your oncologist to see if a clinical trial may be the right fit for you.


Write a Comment

Your email address will not be published. Required fields are marked *